Key facts
- Synplogen’s last known valuation is $50.8M (Jan 2025).
- It has raised $31.5M; the latest was Later Stage VC ($3.8M) in Jan 2025.
- Notable investors include Yagami Manufacturing, Fujifilm Holdings, I-nest Capital, Jafco, Kansai Felt Fabric — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Synplogen
- ·The full record, as it builds
Funding rounds
No funding rounds for Synplogen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synplogen
Developer of a genetic engineering platform designed to perform deoxyribonucleic acid synthesis. The company's platform offers long-chain DNA synthesis support for creating production-use microbes and combinatorial DNA library synthesis, enabling medical professionals to overcome the problems of DNA synthesis.
- Sector
- Healthcare
- HQ
- Kobe, Japan
- Founded
- 2017
- Website
- synplogen.com/
- Ownership
- Privately Held (backing)
Synplogen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synplogen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synplogen in its N-PORT filings yet. We sweep new filings monthly.